Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-1|1|27|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-2|1|513|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-3|1|513|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-4|1|513|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-5|1|520|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-6|1|558|Other deterministic changes|Lower respiratory system|n/a|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-7|1|681|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-8|1|747|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-9|1|761|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-11-1|Gaf+Mo-Gy 2.66,2/85|1|92|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w}|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-1-10|1|775|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-1|2|27|Neoplasia malignant|Reproductive system,MA: 0000381 - female reproductive system|,MPATH: 551 - sarcoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-2|2|282|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-3|2|282|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-4|2|401|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-5|2|456|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-6|2|506|Other deterministic changes|Lower respiratory system|n/a|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-7|2|548|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-8|2|548|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-9|2|555|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-10|2|555|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-11|2|562|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-12|2|583|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-13|2|616|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-14|2|618|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-15|2|639|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-16|2|667|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-17|2|673|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-18|2|705|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-19|2|842|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-2|Gaf+Mo-Gy 5.96,2/85|1|92|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w)|20 (20 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Mothers lifespan study|2-11-2-20|2|882|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-1|3|205|Other deterministic changes|Lower respiratory system|n/a|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-2|3|597|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-3|3|644|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-4|3|644|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-5|3|812|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-6|3|836|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-7|3|886|Other deterministic changes|Lower respiratory system|n/a|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-8|3|886|Other deterministic changes|Lower respiratory system|n/a|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-9|3|886|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-3|Gam+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|10 (10 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Preconception|offspring lifespan study|2-11-3-10|3|886|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-4|Gaf+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|5 (5 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Preconception|offspring lifespan study|2-11-4-1|4|99|Other deterministic changes|Lower respiratory system|n/a|
2-11-4|Gaf+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|5 (5 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Preconception|offspring lifespan study|2-11-4-2|4|99|Other deterministic changes|Lower respiratory system|n/a|
2-11-4|Gaf+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|5 (5 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Preconception|offspring lifespan study|2-11-4-3|4|225|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-11-4|Gaf+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|5 (5 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Preconception|offspring lifespan study|2-11-4-4|4|795|Other deterministic changes|Lower respiratory system|n/a|
2-11-4|Gaf+7d-Gy 2.66,1/80|1|-28|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w mother irrad.from 7d prior conception)|5 (5 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Preconception|offspring lifespan study|2-11-4-5|4|882|Other deterministic changes|Lower respiratory system|n/a|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-1|5|455|Other deterministic changes|Lower respiratory system|n/a|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-2|5|469|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-3|5|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-4|5|503|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-5|5|530|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-6|5|545|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-7|5|580|Other deterministic changes|Lower respiratory system|n/a|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-8|5|581|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-9|5|587|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-10|5|591|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-11|5|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-12|5|670|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-13|5|675|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-14|5|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-15|5|693|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-16|5|693|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-17|5|696|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-18|5|700|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-19|5|700|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-20|5|720|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-21|5|724|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-22|5|728|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-23|5|731|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-24|5|738|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-25|5|760|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-26|5|763|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-27|5|763|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-28|5|770|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-29|5|773|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-30|5|780|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-31|5|790|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-32|5|790|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-33|5|790|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-34|5|803|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-35|5|809|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-36|5|815|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-37|5|815|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-38|5|826|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-39|5|826|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-40|5|837|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-41|5|839|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-42|5|844|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-43|5|844|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-44|5|846|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-45|5|846|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-46|5|849|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-47|5|853|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-48|5|860|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-49|5|867|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-50|5|874|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-51|5|874|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-52|5|874|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-53|5|879|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-54|5|888|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-55|5|905|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-56|5|909|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-57|5|916|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-58|5|923|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-59|5|923|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-60|5|947|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-61|5|947|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-62|5|950|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-63|5|958|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-64|5|963|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-5|Gam+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|65 (65 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-5-65|5|998|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-1|6|171|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-2|6|266|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-3|6|392|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-4|6|420|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-5|6|525|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-6|6|553|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-7|6|587|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-8|6|592|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-9|6|613|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-10|6|619|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-11|6|626|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-12|6|635|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-13|6|637|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-14|6|658|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-15|6|680|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-16|6|682|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-17|6|689|Other deterministic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-18|6|703|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-19|6|710|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-20|6|714|Other deterministic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-21|6|714|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-22|6|719|Neoplasia malignant|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-23|6|728|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-24|6|729|Hyperplastic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-25|6|735|Neoplasia malignant|Adrenal gland  among endocrine systems|metastatic|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-26|6|738|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-27|6|740|Neoplasia malignant|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-28|6|740|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-29|6|741|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-30|6|741|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-31|6|742|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-32|6|759|Neoplasia benign|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-33|6|766|Other deterministic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-34|6|770|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-35|6|770|Other deterministic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-36|6|777|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-37|6|790|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-38|6|791|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-39|6|796|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-40|6|798|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 551 - sarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-41|6|798|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-42|6|798|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-43|6|799|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-44|6|803|Neoplasia malignant|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-45|6|804|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-46|6|811|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-47|6|811|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-48|6|817|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-49|6|830|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-50|6|831|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-51|6|849|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-52|6|856|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-53|6|860|Neoplasia unclassified|Reproductive system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-54|6|860|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-55|6|860|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-56|6|888|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-57|6|891|Other deterministic changes|Lower respiratory system|n/a|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-58|6|901|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-59|6|902|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-60|6|902|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-61|6|914|Neoplasia unclassified|Reproductive system|benign|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-62|6|919|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-63|6|919|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-64|6|958|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-65|6|964|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-6|Gaf+8d-Gy 2.66,2/85|1|-8|gamma-rays Co-60|2.66|grays|External exposure|dose rate 53 mGy/h (4,5h/d 5d/w day 8 postc. to birth)|66 (66 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-6-66|6|964|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-1|7|119|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-2|7|196|Other deterministic changes|Lower respiratory system|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-3|7|339|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-4|7|362|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-5|7|420|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-6|7|427|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-7|7|439|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-8|7|469|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-9|7|521|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-10|7|530|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-11|7|553|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-12|7|556|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-13|7|566|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-14|7|573|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-15|7|574|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-16|7|587|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-17|7|587|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-18|7|591|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-19|7|615|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-20|7|621|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-21|7|621|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-22|7|626|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-23|7|637|Neoplasia unclassified|Reproductive system,MA: 0002420 - gonad|metastatic,MPATH: 322 - teratoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-24|7|658|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-25|7|664|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-26|7|665|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-27|7|675|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-28|7|684|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-29|7|689|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-30|7|693|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-31|7|706|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-32|7|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-33|7|717|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-34|7|735|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-35|7|735|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-36|7|738|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-37|7|742|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-38|7|744|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-39|7|749|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-40|7|752|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-41|7|770|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-42|7|770|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-43|7|776|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-44|7|780|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-45|7|784|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-46|7|791|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-47|7|791|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-48|7|796|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-49|7|801|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-50|7|803|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-51|7|808|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-52|7|809|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-53|7|829|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-54|7|835|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-55|7|835|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-56|7|860|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-57|7|870|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-58|7|874|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-59|7|879|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-60|7|916|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-61|7|944|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-62|7|950|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-7|Gam+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|63 (63 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-7-63|7|963|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-1|8|350|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-2|8|375|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-3|8|427|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-4|8|439|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-5|8|503|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-6|8|511|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-7|8|518|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-8|8|553|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-9|8|556|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-10|8|591|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-11|8|602|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-12|8|606|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-13|8|609|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-14|8|615|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-15|8|630|Neoplasia malignant|Liver among hepato-pancreatic system diseases|metastatic|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-16|8|640|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-17|8|648|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-18|8|657|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-19|8|672|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-20|8|672|Neoplasia malignant|Reproductive system,MA: 0000411 - testis|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-21|8|672|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-22|8|672|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-23|8|675|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-24|8|683|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-25|8|683|Neoplasia unclassified|Reproductive system|metastatic|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-26|8|696|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-27|8|698|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-28|8|714|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-29|8|717|Other deterministic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-30|8|720|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-31|8|724|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-32|8|728|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-33|8|728|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-34|8|728|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-35|8|728|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-36|8|738|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-37|8|752|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-38|8|752|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-39|8|756|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-40|8|763|Neoplasia malignant|Liver among hepato-pancreatic system diseases|metastatic|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-41|8|763|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-42|8|766|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-43|8|766|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-44|8|768|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-45|8|775|Neoplasia unclassified|Reproductive system|benign|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-46|8|777|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-47|8|777|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-48|8|782|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-49|8|791|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-50|8|798|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-51|8|798|Hyperplastic changes|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-52|8|798|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-53|8|801|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-54|8|803|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-55|8|808|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-56|8|811|Neoplasia unclassified|Reproductive system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-57|8|815|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-58|8|829|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|benign,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-59|8|830|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-60|8|831|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-61|8|839|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-62|8|839|Neoplasia unclassified|Reproductive system|benign|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-63|8|849|Neoplasia benign|Lower respiratory system|n/a|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-64|8|853|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-65|8|871|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-66|8|881|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-67|8|901|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-68|8|909|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-8|Gaf+8d-Gy 5.96,2/85|1|-8|gamma-rays Co-60|5.96|grays|External exposure|dose rate 53 mGy/h (3,5h/d 5d/w day 8 pc to 1 m)|69 (69 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-8-69|8|923|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-1|9|191|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-2|9|195|Other deterministic changes|Lower respiratory system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-3|9|209|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-4|9|244|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-5|9|244|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-6|9|284|Other deterministic changes|Lower respiratory system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-7|9|300|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-8|9|310|Other deterministic changes|Lower respiratory system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-9|9|377|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-10|9|398|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-11|9|412|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-12|9|433|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-13|9|443|Neoplasia benign|Lower respiratory system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-14|9|447|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-15|9|450|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-16|9|468|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-17|9|468|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-18|9|473|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-19|9|475|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-20|9|492|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-21|9|496|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-22|9|502|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-23|9|510|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-24|9|510|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-25|9|510|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-26|9|552|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-27|9|559|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-28|9|573|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-29|9|577|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-30|9|580|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-31|9|590|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-32|9|619|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-33|9|619|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-34|9|621|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-35|9|634|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-36|9|636|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-37|9|641|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-38|9|643|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-39|9|657|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-40|9|695|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-41|9|699|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-42|9|702|Other deterministic changes|Lower respiratory system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-43|9|703|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-44|9|716|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-45|9|724|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-46|9|734|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-47|9|744|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-48|9|744|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-49|9|755|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-50|9|762|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-51|9|776|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-52|9|800|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-53|9|802|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-54|9|838|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-55|9|843|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-9|Gam+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|56 (56 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Prenatal|offspring lifespan study|2-11-9-56|9|963|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-1|10|243|Other deterministic changes|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-2|10|344|Other deterministic changes|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-3|10|360|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-4|10|376|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-5|10|383|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-6|10|390|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-7|10|425|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-8|10|428|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-9|10|462|Other deterministic changes|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-10|10|463|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-11|10|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-12|10|474|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-13|10|505|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-14|10|509|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-15|10|528|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-16|10|533|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-17|10|533|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-18|10|543|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-19|10|558|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-20|10|558|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-21|10|558|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-22|10|564|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-23|10|583|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 551 - sarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-24|10|585|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-25|10|593|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-26|10|603|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-27|10|620|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-28|10|620|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-29|10|633|Neoplasia malignant|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-30|10|633|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-31|10|640|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-32|10|640|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-33|10|666|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-34|10|670|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-35|10|682|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-36|10|687|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-37|10|691|Neoplasia malignant|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-38|10|701|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-39|10|729|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|metastatic|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-40|10|733|Hyperplastic changes|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-41|10|741|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-42|10|743|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-43|10|747|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-44|10|775|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-45|10|782|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-46|10|782|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-47|10|794|Neoplasia malignant|Lower respiratory system|n/a|
2-11-10|Gaf+8d-Gy 14.74,2/85|1|92|gamma-rays Co-60|14.74|grays|External exposure|dose rate 53 mGy/h (3h/d 5d/w day 8 pc to 140 d)|48 (48 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Prenatal|offspring lifespan study|2-11-10-48|10|868|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-1|11|4|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-2|11|7|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-3|11|7|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-4|11|11|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-5|11|11|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-6|11|11|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-7|11|16|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-8|11|21|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-9|11|23|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-10|11|31|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-11|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-12|11|31|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-13|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-14|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-15|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-16|11|31|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-17|11|31|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-18|11|31|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-19|11|34|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-20|11|48|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-21|11|60|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-22|11|60|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-23|11|60|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-24|11|60|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-25|11|310|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-26|11|315|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-27|11|328|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-28|11|353|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-29|11|355|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-30|11|357|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-31|11|364|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-32|11|377|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-33|11|408|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-34|11|408|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-35|11|435|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-36|11|450|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-37|11|454|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-38|11|460|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-39|11|476|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-40|11|480|Hyperplastic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-41|11|484|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-42|11|497|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-43|11|506|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-44|11|507|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-45|11|507|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-46|11|508|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-47|11|513|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-48|11|515|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-49|11|515|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-50|11|517|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-51|11|520|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-52|11|531|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-53|11|537|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-54|11|537|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-55|11|540|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-56|11|554|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-57|11|554|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-58|11|556|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-59|11|559|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-60|11|561|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-61|11|561|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-62|11|568|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-63|11|572|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-64|11|574|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-65|11|576|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-66|11|576|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-67|11|577|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-68|11|579|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-69|11|588|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-70|11|588|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-71|11|591|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-72|11|594|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-73|11|594|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-74|11|601|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-75|11|604|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-76|11|609|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-77|11|609|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-78|11|609|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-79|11|616|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-80|11|617|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-81|11|618|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-82|11|619|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-83|11|620|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-84|11|626|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-85|11|627|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-86|11|627|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-87|11|636|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-88|11|636|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-89|11|639|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-90|11|639|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-91|11|641|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-92|11|641|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-93|11|641|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-94|11|644|Neoplasia malignant|Lower digestive tract,MA: 0001900 - gastrointestinal system mesentery|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-95|11|644|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-96|11|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-97|11|644|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-98|11|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-99|11|651|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-100|11|651|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-101|11|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-102|11|654|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-103|11|657|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-104|11|658|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-105|11|658|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-106|11|659|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-107|11|659|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-108|11|663|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-109|11|664|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-110|11|665|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-111|11|665|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-112|11|665|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-113|11|665|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-114|11|666|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-115|11|673|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-116|11|680|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-117|11|681|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-118|11|683|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-119|11|684|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-120|11|686|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-121|11|686|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-122|11|688|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-123|11|694|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-124|11|694|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-125|11|694|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-126|11|694|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-127|11|694|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-128|11|694|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-129|11|694|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-130|11|694|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-131|11|697|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-132|11|697|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-133|11|699|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-134|11|700|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-135|11|700|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-136|11|701|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-137|11|701|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-138|11|701|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-139|11|703|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-140|11|704|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-141|11|705|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-142|11|707|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-143|11|707|Neoplasia benign|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-144|11|707|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-145|11|707|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-146|11|709|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-147|11|715|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-148|11|718|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-149|11|721|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-150|11|721|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-151|11|721|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-152|11|721|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-153|11|721|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-154|11|725|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-155|11|726|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-156|11|728|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-157|11|728|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-158|11|728|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-159|11|728|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-160|11|728|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-161|11|729|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-162|11|729|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-163|11|731|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-164|11|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-165|11|732|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-166|11|732|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-167|11|732|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-168|11|733|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-169|11|735|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-170|11|736|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-171|11|736|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-172|11|740|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-173|11|741|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-174|11|741|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-175|11|742|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-176|11|742|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-177|11|743|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-178|11|746|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-179|11|747|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-180|11|747|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-181|11|747|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-182|11|747|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-183|11|749|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-184|11|749|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-185|11|749|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-186|11|749|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-187|11|751|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-188|11|753|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-189|11|753|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-190|11|753|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-191|11|753|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-192|11|753|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-193|11|753|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-194|11|755|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-195|11|756|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-196|11|764|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-197|11|764|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-198|11|764|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-199|11|765|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-200|11|765|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-201|11|767|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-202|11|767|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-203|11|767|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-204|11|768|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-205|11|768|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-206|11|768|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-207|11|768|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-208|11|768|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-209|11|768|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-210|11|768|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-211|11|770|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-212|11|770|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-213|11|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-214|11|770|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-215|11|772|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-216|11|772|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-217|11|774|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-218|11|774|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-219|11|775|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-220|11|776|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-221|11|776|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-222|11|778|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-223|11|778|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-224|11|780|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-225|11|780|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-226|11|780|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-227|11|780|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-228|11|782|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-229|11|783|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-230|11|783|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-231|11|783|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-232|11|784|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-233|11|786|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-234|11|787|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-235|11|787|Neoplasia unclassified|Reproductive system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-236|11|787|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-237|11|787|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-238|11|787|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-239|11|787|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-240|11|787|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-241|11|787|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-242|11|787|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-243|11|787|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-244|11|787|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-245|11|787|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-246|11|789|Neoplasia unclassified|Nervous system and special sense organs,MA: 0002565 - sebaceous gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-247|11|789|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-248|11|789|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-249|11|793|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-250|11|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-251|11|793|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-252|11|794|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-253|11|794|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-254|11|794|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-255|11|795|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|benign,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-256|11|800|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-257|11|800|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-258|11|800|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-259|11|800|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-260|11|800|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-261|11|800|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-262|11|800|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-263|11|801|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-264|11|801|Neoplasia benign|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-265|11|801|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-266|11|807|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-267|11|807|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-268|11|808|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-269|11|808|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-270|11|810|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-271|11|810|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-272|11|810|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-273|11|810|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-274|11|810|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-275|11|813|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-276|11|815|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-277|11|815|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-278|11|815|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-279|11|816|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-280|11|816|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-281|11|817|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-282|11|818|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-283|11|820|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-284|11|822|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-285|11|822|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-286|11|822|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-287|11|822|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-288|11|822|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-289|11|822|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-290|11|824|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-291|11|824|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-292|11|825|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-293|11|825|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-294|11|825|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-295|11|829|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-296|11|829|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-297|11|829|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-298|11|829|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-299|11|831|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-300|11|831|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-301|11|834|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|metastatic,MPATH: 511 - Myeloproliferation (genetic)|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-302|11|834|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-303|11|835|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-304|11|839|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-305|11|843|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-306|11|843|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-307|11|843|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-308|11|843|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-309|11|843|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-310|11|843|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-311|11|843|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-312|11|843|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-313|11|843|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-314|11|845|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-315|11|845|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-316|11|846|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-317|11|846|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-318|11|846|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-319|11|846|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-320|11|846|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-321|11|846|Hyperplastic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-322|11|847|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-323|11|847|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-324|11|850|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-325|11|850|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-326|11|852|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-327|11|853|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-328|11|854|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-329|11|854|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-330|11|855|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-331|11|855|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-332|11|856|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-333|11|856|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-334|11|856|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-335|11|857|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-336|11|857|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-337|11|857|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-338|11|857|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-339|11|857|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-340|11|857|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-341|11|857|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-342|11|861|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-343|11|862|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-344|11|862|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-345|11|862|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-346|11|862|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-347|11|863|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-348|11|863|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-349|11|863|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-350|11|863|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-351|11|863|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-352|11|864|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-353|11|864|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-354|11|867|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-355|11|868|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-356|11|868|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-357|11|869|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-358|11|871|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-359|11|871|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-360|11|871|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-361|11|871|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-362|11|871|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-363|11|873|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-364|11|873|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-365|11|874|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-366|11|874|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-367|11|874|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-368|11|874|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-369|11|874|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-370|11|876|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-371|11|877|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-372|11|877|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-373|11|877|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-374|11|877|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-375|11|877|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-376|11|878|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-377|11|881|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-378|11|881|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-379|11|881|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-380|11|883|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-381|11|883|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-382|11|883|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-383|11|884|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-384|11|884|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-385|11|884|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-386|11|885|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-387|11|885|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-388|11|885|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-389|11|887|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-390|11|891|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-391|11|891|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-392|11|891|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-393|11|891|Hyperplastic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-394|11|892|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-395|11|892|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-396|11|892|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-397|11|892|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-398|11|893|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-399|11|895|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-400|11|895|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-401|11|896|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-402|11|898|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-403|11|898|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-404|11|898|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-405|11|898|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-406|11|899|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-407|11|900|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-408|11|901|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-409|11|902|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-410|11|902|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-411|11|902|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-412|11|905|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-413|11|906|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-414|11|906|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-415|11|906|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-416|11|909|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-417|11|909|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-418|11|909|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-419|11|912|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-420|11|913|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-421|11|916|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-422|11|916|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-423|11|919|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-424|11|920|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-425|11|920|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-426|11|920|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-427|11|920|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-428|11|923|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-429|11|924|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-430|11|924|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-431|11|926|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-432|11|927|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-433|11|927|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-434|11|927|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-435|11|928|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-436|11|929|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-437|11|929|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-438|11|930|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-439|11|933|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-440|11|933|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-441|11|933|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-442|11|933|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-443|11|933|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-444|11|936|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-445|11|936|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-446|11|936|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-447|11|937|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-448|11|937|Neoplasia malignant|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-449|11|937|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-450|11|937|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-451|11|941|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-452|11|941|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-453|11|941|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-454|11|941|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-455|11|944|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-456|11|944|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-457|11|944|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-458|11|944|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-459|11|944|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-460|11|947|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-461|11|947|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-462|11|947|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-463|11|947|Inflammation and/or fibrotic diseases|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 213 - acute inflammation|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-464|11|947|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-465|11|948|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-466|11|949|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-467|11|949|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-468|11|950|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-469|11|951|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-470|11|951|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-471|11|952|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-472|11|955|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-473|11|955|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-474|11|955|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-475|11|955|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-476|11|955|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-477|11|959|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-478|11|962|Neoplasia malignant|Heart among cardiovascular system,MA: 0000072 - heart|,MPATH: 511 - Myeloproliferation (genetic)|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-479|11|962|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-480|11|962|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-481|11|963|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-482|11|963|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-483|11|965|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-484|11|965|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-485|11|969|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-486|11|969|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-487|11|969|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-488|11|969|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-489|11|972|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-490|11|972|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-491|11|975|Neoplasia benign|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-492|11|976|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-493|11|976|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-494|11|979|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-495|11|979|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-496|11|982|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-497|11|982|Other deterministic changes|Lower respiratory system|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-498|11|983|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-499|11|983|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-500|11|996|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-501|11|996|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-502|11|996|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-503|11|997|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-504|11|997|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-11|Gam+3m-Gy 1,82-83|1|92|gamma-rays Co-60|1|grays|External exposure|dose rate 87 mGy/h .6h/d 5d)|505 (505 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-11-505|11|997|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-1|12|249|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-2|12|257|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-3|12|291|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-4|12|312|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-5|12|315|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-6|12|315|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-7|12|325|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-8|12|340|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-9|12|340|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-10|12|350|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-11|12|361|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-12|12|361|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-13|12|368|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-14|12|395|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-15|12|395|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-16|12|398|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-17|12|400|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-18|12|400|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-19|12|411|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-20|12|421|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-21|12|422|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-22|12|423|Neoplasia benign|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-23|12|431|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-24|12|432|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-25|12|432|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-26|12|435|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-27|12|446|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-28|12|446|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-29|12|446|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-30|12|451|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-31|12|457|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-32|12|466|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-33|12|471|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-34|12|477|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-35|12|479|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-36|12|508|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-37|12|515|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-38|12|519|Neoplasia benign|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-39|12|523|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-40|12|529|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-41|12|540|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-42|12|540|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-43|12|542|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-44|12|549|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-45|12|549|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-46|12|557|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-47|12|562|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-48|12|563|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-49|12|569|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-50|12|572|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-51|12|575|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-52|12|586|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|benign,MPATH: 354 - cholangiocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-53|12|591|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-54|12|594|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|benign,MPATH: 242 - hemangiosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-55|12|599|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-56|12|601|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-57|12|601|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-58|12|603|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-59|12|604|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-60|12|604|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-61|12|605|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-62|12|610|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-63|12|613|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-64|12|613|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 409 - fibrous histiocytoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-65|12|613|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-66|12|617|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-67|12|622|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-68|12|625|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-69|12|625|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-70|12|625|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-71|12|626|Neoplasia malignant|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-72|12|626|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-73|12|626|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-74|12|631|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-75|12|633|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-76|12|633|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-77|12|633|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-78|12|638|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-79|12|638|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-80|12|639|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-81|12|639|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-82|12|645|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-83|12|649|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-84|12|652|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-85|12|652|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-86|12|652|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-87|12|655|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-88|12|655|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-89|12|661|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-90|12|661|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-91|12|661|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-92|12|663|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-93|12|663|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-94|12|666|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-95|12|666|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-96|12|670|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-97|12|673|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-98|12|680|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-99|12|682|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-100|12|682|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-101|12|684|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-102|12|687|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-103|12|690|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-104|12|696|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-105|12|705|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-106|12|715|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-107|12|715|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-108|12|717|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-109|12|717|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-110|12|717|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-111|12|717|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-112|12|718|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-113|12|718|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-114|12|718|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-115|12|718|Neoplasia malignant|Lymphatic vessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-116|12|719|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-117|12|719|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-118|12|723|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-119|12|725|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-120|12|725|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-121|12|731|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-122|12|731|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-123|12|733|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-124|12|738|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-125|12|738|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-126|12|739|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-127|12|740|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-128|12|740|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-129|12|742|Neoplasia benign|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-130|12|742|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-131|12|744|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-132|12|745|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-133|12|745|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-134|12|745|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-135|12|745|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-136|12|747|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-137|12|750|Neoplasia malignant|Lower digestive tract,MA: 0001900 - gastrointestinal system mesentery|metastatic,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-138|12|750|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-139|12|750|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-140|12|750|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-141|12|751|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-142|12|752|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-143|12|752|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-144|12|754|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-145|12|754|Neoplasia benign|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-146|12|754|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-147|12|757|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-148|12|757|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-149|12|757|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-150|12|757|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-151|12|759|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-152|12|759|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-153|12|759|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-154|12|759|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-155|12|759|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-156|12|759|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-157|12|759|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-158|12|764|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-159|12|765|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-160|12|765|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-161|12|767|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-162|12|767|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-163|12|769|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-164|12|769|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-165|12|771|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-166|12|780|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-167|12|780|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-168|12|780|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-169|12|780|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-170|12|785|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-171|12|786|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-172|12|789|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-173|12|789|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-174|12|789|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-175|12|794|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-176|12|794|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-177|12|794|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-178|12|794|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-179|12|794|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-180|12|794|Hyperplastic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-181|12|795|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-182|12|795|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-183|12|795|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-184|12|795|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-185|12|795|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-186|12|796|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-187|12|796|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-188|12|799|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-189|12|800|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-190|12|800|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-191|12|800|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-192|12|803|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-193|12|803|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-194|12|803|Neoplasia benign|Lower respiratory system,MA: 0000415 - lung|,MPATH: 240 - hemangioma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-195|12|806|Hyperplastic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-196|12|806|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-197|12|807|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-198|12|811|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-199|12|816|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-200|12|816|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-201|12|817|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-202|12|820|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-203|12|820|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-204|12|820|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-205|12|821|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-206|12|821|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-207|12|821|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-208|12|821|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-209|12|821|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-210|12|822|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-211|12|822|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-212|12|823|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-213|12|823|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-214|12|824|Hyperplastic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-215|12|824|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-216|12|828|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-217|12|829|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-218|12|829|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-219|12|834|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-220|12|838|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-221|12|841|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-222|12|841|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-223|12|841|Neoplasia malignant|Upper digestive tract,MA: 0000341 - oral region|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-224|12|841|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-225|12|842|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-226|12|845|Neoplasia benign|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-227|12|845|Neoplasia malignant|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-228|12|845|Hyperplastic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-229|12|848|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-230|12|850|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-231|12|850|Neoplasia malignant|Liver among hepato-pancreatic system diseases|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-232|12|850|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-233|12|851|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-234|12|852|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-235|12|852|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-236|12|852|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-237|12|852|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-238|12|852|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-239|12|855|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-240|12|855|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-241|12|855|Neoplasia benign|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-242|12|862|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-243|12|862|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-244|12|863|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-245|12|872|Hyperplastic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-246|12|872|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-247|12|875|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-248|12|876|Neoplasia unclassified|Lower respiratory system,MA: 0000032 - thoracic cavity|,MPATH: 238 - hemangioblastoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-249|12|876|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-250|12|877|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-251|12|878|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-252|12|879|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000565 - mesothelium|,MPATH: 365 - mesothelioma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-253|12|883|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-254|12|883|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-255|12|883|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-256|12|883|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-257|12|884|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-258|12|884|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-259|12|884|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-260|12|887|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000565 - mesothelium|metastatic,MPATH: 365 - mesothelioma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-261|12|887|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-262|12|890|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-263|12|890|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-264|12|890|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-265|12|890|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-266|12|893|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-267|12|897|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-268|12|897|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-269|12|899|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-270|12|904|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-271|12|904|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-272|12|905|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-273|12|907|Neoplasia malignant|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-274|12|911|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-275|12|911|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-276|12|911|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-277|12|912|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-278|12|914|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-279|12|915|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-280|12|915|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-281|12|915|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-282|12|918|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-283|12|921|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-284|12|921|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-285|12|926|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-286|12|926|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-287|12|934|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-288|12|934|Other deterministic changes|Lower respiratory system|n/a|
2-11-12|Gam+3m-Gy 2.83,8/86|1|275|gamma-rays Co-60|2.83|grays|External exposure|dose rate 1.34 mGy/h (h/d 7d/w 14w)|289 (289 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-12-289|12|949|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-1|13|40|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-2|13|199|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-3|13|351|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-4|13|366|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-5|13|385|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-6|13|408|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-7|13|420|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-8|13|440|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-9|13|442|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-10|13|475|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-11|13|538|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-12|13|538|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-13|13|562|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-14|13|574|Neoplasia benign|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-15|13|583|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-16|13|591|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-17|13|595|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-18|13|595|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-19|13|605|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-20|13|605|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-21|13|610|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-22|13|616|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-23|13|626|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-24|13|633|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-25|13|637|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-26|13|645|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-27|13|650|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-28|13|651|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-29|13|655|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-30|13|655|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-31|13|661|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-32|13|664|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-33|13|671|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-34|13|685|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|benign,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-35|13|689|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-36|13|689|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-37|13|701|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 242 - hemangiosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-38|13|701|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-39|13|701|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-40|13|701|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-41|13|701|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-42|13|711|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-43|13|711|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-44|13|714|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-45|13|720|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-46|13|725|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-47|13|726|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-48|13|729|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-49|13|730|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-50|13|732|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-51|13|732|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-52|13|748|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-53|13|748|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-54|13|748|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-55|13|748|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-56|13|750|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-57|13|750|Neoplasia malignant|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-58|13|753|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-59|13|754|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-60|13|756|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-61|13|760|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-62|13|760|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-63|13|770|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-64|13|770|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-65|13|777|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-66|13|781|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-67|13|784|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-68|13|784|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-69|13|785|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-70|13|791|Neoplasia benign|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-71|13|791|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-72|13|791|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-73|13|795|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-74|13|795|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-75|13|802|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-76|13|805|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-77|13|806|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-78|13|806|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-79|13|810|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-80|13|815|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-81|13|816|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-82|13|816|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-83|13|816|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-84|13|819|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-85|13|819|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-86|13|819|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-87|13|831|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-88|13|833|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-89|13|833|Hyperplastic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-90|13|833|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-91|13|844|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-92|13|854|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-93|13|858|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-94|13|864|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-95|13|865|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-96|13|871|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|benign,MPATH: 219 - adnexal and skin appendage tumor|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-97|13|872|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-98|13|872|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-99|13|875|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-100|13|875|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-101|13|879|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-102|13|882|Other deterministic changes|Lower respiratory system|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-103|13|897|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-104|13|904|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-105|13|911|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-106|13|911|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-107|13|911|Neoplasia malignant|Adrenal gland  among endocrine systems|n/a|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-108|13|918|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-109|13|921|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-110|13|921|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-111|13|946|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-112|13|960|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-113|13|960|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-114|13|960|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-115|13|963|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-116|13|998|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|metastatic,MPATH: 219 - adnexal and skin appendage tumor|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-117|13|998|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-118|13|998|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-119|13|998|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-13|Gam+3m-Gy 3,11/8|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 87 mGy/h (6.3h/d 5d)|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|lifespan study|2-11-13-120|13|998|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-1|14|411|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-2|14|452|Other deterministic changes|Lower respiratory system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-3|14|490|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-4|14|497|Other deterministic changes|Lower respiratory system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-5|14|498|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-6|14|517|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-7|14|517|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-8|14|539|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-9|14|545|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-10|14|564|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-11|14|574|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-12|14|582|Neoplasia malignant|Lymphatic vessels among cardiovascular system|metastatic|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-13|14|594|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-14|14|609|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-15|14|631|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-16|14|634|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-17|14|654|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-18|14|661|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-19|14|665|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-20|14|669|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-21|14|671|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-22|14|672|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-23|14|672|Other deterministic changes|Lower respiratory system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-24|14|684|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-25|14|689|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-26|14|692|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-27|14|697|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-28|14|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-29|14|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-30|14|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-31|14|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-32|14|706|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-33|14|706|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-34|14|707|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-35|14|719|Neoplasia malignant|Reproductive system,MA: 0000396 - male reproductive system|,MPATH: 551 - sarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-36|14|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-37|14|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-38|14|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-39|14|719|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-40|14|741|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-41|14|741|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-42|14|760|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-43|14|781|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-44|14|782|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-45|14|783|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-46|14|783|Neoplasia systemic|Haematolymphatic system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-47|14|789|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-48|14|802|Other deterministic changes|Lower respiratory system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-49|14|803|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-50|14|820|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-51|14|826|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-52|14|854|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-53|14|861|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-54|14|879|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-55|14|904|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-56|14|908|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-57|14|908|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|benign,MPATH: 218 - neoplasm|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-58|14|928|Other deterministic changes|Lower respiratory system|n/a|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-59|14|936|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-14|Gam+9m-Gy 3,1/88|1|9|gamma-rays Co-60|3|grays|External exposure|dose rate 38 mGy/h during 5 d|60 (60 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Adult|lifespan study|2-11-14-60|14|936|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-1|15|416|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-2|15|427|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-3|15|484|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-4|15|490|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-5|15|504|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-6|15|543|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-7|15|547|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-8|15|550|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-9|15|557|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-10|15|557|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-11|15|582|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-12|15|588|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-13|15|610|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-14|15|613|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-15|15|613|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-16|15|622|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 409 - fibrous histiocytoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-17|15|629|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-18|15|634|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-19|15|655|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 551 - sarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-20|15|665|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-21|15|673|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-22|15|675|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-23|15|675|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-24|15|682|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-25|15|685|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-26|15|686|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-27|15|689|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-28|15|696|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-29|15|703|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-30|15|704|Hyperplastic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-31|15|706|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-32|15|706|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-33|15|707|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-34|15|712|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-35|15|713|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-36|15|717|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-37|15|719|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-38|15|719|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-39|15|719|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-40|15|725|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-41|15|726|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-42|15|726|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-43|15|727|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 551 - sarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-44|15|732|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-45|15|733|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-46|15|733|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-47|15|735|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-48|15|736|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-49|15|736|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-50|15|741|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-51|15|741|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-52|15|741|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-53|15|747|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-54|15|747|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-55|15|754|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-56|15|756|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-57|15|756|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-58|15|760|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-59|15|761|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-60|15|761|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-61|15|761|Neoplasia benign|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-62|15|767|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-63|15|768|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-64|15|768|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-65|15|774|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-66|15|778|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-67|15|781|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-68|15|781|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-69|15|782|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-70|15|788|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-71|15|791|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-72|15|791|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-73|15|798|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-74|15|802|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-75|15|802|Hyperplastic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-76|15|803|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-77|15|804|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-78|15|809|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-79|15|809|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-80|15|810|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-81|15|816|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-82|15|826|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-83|15|826|Neoplasia malignant|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-84|15|830|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-85|15|830|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-86|15|833|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-87|15|833|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-88|15|837|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-89|15|837|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-90|15|837|Neoplasia malignant|Lymphatic vessels among cardiovascular system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-91|15|840|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-92|15|851|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-93|15|853|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-94|15|854|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-95|15|858|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-96|15|858|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-97|15|861|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-98|15|867|Neoplasia benign|Lower respiratory system,MA: 0000433 - pleura|,MPATH: 365 - mesothelioma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-99|15|867|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-100|15|869|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-101|15|872|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-102|15|874|Neoplasia malignant|Lymphatic vessels among cardiovascular system|benign|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-103|15|880|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|metastatic lung tumour,MPATH: 212 - inflammation|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-104|15|880|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-105|15|890|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-106|15|890|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-107|15|900|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-108|15|902|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-109|15|902|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-110|15|904|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-111|15|909|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-112|15|914|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-113|15|914|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-114|15|918|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-115|15|928|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-116|15|952|Other deterministic changes|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-117|15|970|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|benign,MPATH: 242 - hemangiosarcoma|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-118|15|970|Neoplasia benign|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-119|15|970|Neoplasia malignant|Lower respiratory system|n/a|
2-11-15|Gaf+9m-Gy 3,1/88|1|9|gamma-rays Co-60|33|grays|External exposure|dose rate 38 mGy/h during 5 d|120 (120 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Adult|lifespan study|2-11-15-120|15|970|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
